Filing Flows › Abeona Therapeutics (ABEO) › Q3 2026
Abeona Therapeutics (ABEO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Abeona Therapeutics (ABEO) reported revenue of $13.5M for the third quarter 2026 (Q3 2026) and +19% from the quarter before. Operating margin was -96.4%, net loss $4.8M (35.6% of revenue).
Abeona Therapeutics, Q3 2026: revenue $13.5M, operating margin -96.4%, net loss $4.8M, operating cash flow −$8.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.5M | +19% | — |
| Operating profit | −$13.0M | — | — |
| Net earnings | −$4.8M | — | — |
| Operating cash flow | −$8.3M | — | — |
What changed
Revenue was $13.5M in Q3 2026, up 19% from the previous quarter.
Operating costs exceeded revenue by $13.0M, an operating margin of -96.4%. The quarter ended with a net loss of $4.8M, narrower than the previous quarter's $20.2M loss. Non-operating items added $8.2M, so the bottom line overstates operating performance.
Operating cash flow was −$8.3M. Non-cash charges added back $705K of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items used $7.0M. Capital expenditures of $219K exceeded it, leaving free cash flow of −$8.5M.
Questions
What was Abeona Therapeutics' revenue in the third quarter 2026?
Abeona Therapeutics (ABEO) reported revenue of $13.5M for the third quarter 2026 (Q3 2026) and +19% from the quarter before.
Was Abeona Therapeutics profitable in the third quarter 2026?
Operating loss was $13.0M (-96.4% of revenue) and net loss $4.8M.